Market Risers: Anglo Pacific Group, AstraZeneca, British American Tobacco, Bunzl

Broker Ratings
[shareaholic app="share_buttons" id_name="post_below_content"]

Stock in Anglo Pacific Group ticker lookup code: LON:APF has stepped up 4.91% or 9.42 points during today’s session so far. Buyers are a positive bunch during the session. The periods high has reached 203 meanwhile the session low reached 190.5. The amount of shares exchanged has so far reached 177,739 with the daily average number around 164,061. The stock 52 week high is 229 about 37 points in difference on the previous days close and a 52 week low being 135 which is a difference of 57 points. Anglo Pacific Group now has a 20 SMA of 186.66 with a 50 day MA at 194.92. The market capitalisation is now £365.52m at the time of this report. The stock is traded in GBX. Mcap is measured in GBP. This article was written with the last trade for Anglo Pacific Group being recorded at Monday, December 16, 2019 at 12:22:15 PM GMT with the stock price trading at 201.42 GBX.

Shares of AstraZeneca with company EPIC: LON:AZN has increased 3.09% or 223 points during today’s session so far. Investors have stayed positive during the session. The periods high has reached 7447 meanwhile the session low reached 7235. The total volume of shares exchanged through this period comes to 441,816 with the daily average at 1,987,907. The 52 week high is 7646 amounting to 429 points in difference on the previous days close and a 52 week low being 5312 a difference of some 1905 points. AstraZeneca has a 20 SMA of 7417.53 and the 50 day SMA of 7341.22. The market cap now stands at £97,606.35m at the time of this report. The currency for this stock is Great British pence.Market cap is measured in GBP. This article was written with the last trade for AstraZeneca being recorded at Monday, December 16, 2019 at 12:27:49 PM GMT with the stock price trading at 7440 GBX.

Shares in British American Tobacco with ticker code: LON:BATS has climbed 4.29% or 130.5 points throughout today’s trading session so far. Traders have so far held a positive outlook during this period. The period high has peaked at 3198 and hitting a low of 3053. The volume total for shares traded up to this point was 976,854 whilst the daily average number of shares exchanged is just 4,135,814. The 52 week high price for the shares is 3222 about 183 points difference from the previous close and the 52 week low at 2336.5 making a difference of 702.5 points. British American Tobacco has a 20 day moving average of 3019.82 and now its 50 day moving average at 2891.52. The market cap now stands at £72,704.13m at the time of this report. The currency for this stock is Great British pence.Market cap is measured in GBP. This article was written with the last trade for British American Tobacco being recorded at Monday, December 16, 2019 at 12:27:18 PM GMT with the stock price trading at 3169.5 GBX.

The stock price for Bunzl with company EPIC: LON:BNZL has risen 3.2% or 66 points during today’s session so far. Investors have so far held a positive outlook throughout the trading session. The period high has peaked at 2150 and hitting a low of 2065.13. The total volume traded so far comes to 177,698 with the average number of shares traded daily being 882,607. The 52 week high for the share price is 2554.6 amounting to 493.6 points different to the previous business close and a 52 week low sitting at 1891.5 which is a variance of 169.5 points. Bunzl now has a 20 moving average of 2095.86 and also a 50 day MA at 2055.25. The market capitalisation currently stands at £7,163.55m at the time of this report. The share price is in GBX. Mcap is measured in GBP. This article was written with the last trade for Bunzl being recorded at Monday, December 16, 2019 at 12:25:28 PM GMT with the stock price trading at 2127 GBX.

Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:
    AstraZeneca Plc commits $3.5 billion to boost US research and manufacturing by 2026, creating jobs and expanding its innovation footprint.
    AstraZeneca and Amgen's Tezspire shows promise in reducing nasal polyp size and congestion, offering hope for chronic rhinosinusitis patients.
    AstraZeneca's Wainzua gains CHMP backing for EU approval in treating ATTRv-PN, marking a potential breakthrough with self-administered therapy.

      Search

      Search